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Abstract
POU3F4 is a member of the POU-homedomain transcription factor family with a prominent role in inner ear development.
Mutations in the human POU3F4 coding unit leads to X-linked deafness type 3 (DFN3), characterized by conductive hearing
loss and progressive sensorineural deafness. Microdeletions found 1 Mb 59 upstream of the coding region also displayed
the same phenotype, suggesting that cis-regulatory elements might be present in that region. Indeed, we and others have
recently identified several enhancers at the 1 Mb 59 upstream interval of the pou3f4 locus. Here we characterize the spatio-
temporal patterns of these regulatory elements in zebrafish transgenic lines. We show that the most distal enhancer (HCNR
81675) is activated earlier and drives GFP reporter expression initially to a broad ear domain to progressively restrict to the
sensory patches. The proximal enhancer (HCNR 82478) is switched later during development and promotes expression,
among in other tissues, in sensory patches from its onset. The third enhancer (HCNR 81728) is also active at later stages in
the otic mesenchyme and in the otic epithelium. We also characterize the signaling pathways regulating these enhancers.
While HCNR 81675 is regulated by very early signals of retinoic acid, HCNR 82478 is regulated by Fgf activity at a later stage
and the HCNR 81728 enhancer is under the control of Hh signaling. Finally, we show that Sox2 and Pax2 transcription
factors are bound to HCNR 81675 genomic region during otic development and specific mutations to these transcription
factor binding sites abrogates HCNR 81675 enhancer activity. Altogether, our results suggest that pou3f4 expression in inner
ear might be under the control of distinct regulatory elements that fine-tune the spatio-temporal activity of this gene and
provides novel data on the signaling mechanisms controlling pou3f4 function.
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Introduction
The inner ear of vertebrates is one of the most complex sensory
organs of the head and host two senses, the sense of hearing and
the sense of balance. From an ectodermal layer adjacent to the
hindbrain, the otic placode, a spheroid organ is generated by
invagination/cavitation followed by a series of developmental
processes such as patterning, cell diversification and morphogen-
esis. In the ventral portion of the inner ear, the cochlea or auditory
organ emerges as an outpocketing of the otic vesicle, while in the
dorsal portion of the otic vesicle the vestibular organs, semicircular
canals and endolymphatic duct are developed. In each sensory
organ, the main functional unit is composed by the hair-cells, the
supporting cells and the sensory neurons that connect the hair-cells
to the central nervous system [1,2]. The integration of signals in
the inner ear from the surrounding tissues is essential for its proper
development. In recent years, a large number of genes have been
disclosed to participate in the formation of the ear and control
gene activity. Yet, how those interact and are spatio-temporally
regulated is still poorly understood. Highly conserved non-coding
regions (HCNR) have been revealed and proposed to contain key
cis-regulatory elements [3,4]. Emergent characteristics of these
sequences are their evolutionary conservation, their location in the
genome (either upstream or downstream and even in introns from
the gene that regulate), their clustering around transcription
factors and their contributions to disease when mutated [5–7]. To
date, very few regulatory regions controlling inner ear gene
transcription have been identified so far. Recently, a regulatory
region of the Dlx5-Dlx6 genes was found by the study of five
affected members displaying hearing loss and craniofacial defects.
The affected individuals shared a deletion of 5,115 bp. Bioinfor-
matic analysis of this sequence indicated the presence of several
HCNR, which in a transgenic mouse reporter assay, drove
expression in the inner ear and developing bones [8].
The POU proteins are transcription factors that bind to DNA
through their POU-specific and POU-homeodomain regions and
play essential roles during development. Several members of the
POU family are expressed in the inner ear. The gene POU4F3
(Brn3c) is specifically expressed in hair-cells and mutations in
POU4F3 causes DFNA15, an autosomal dominant form of
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progressive hearing loss [9]. Mutations in another member of the
POU family, the POU3F4 (Brn4) causes deafness type 3 (DFN3),
characterized by a conductive hearing loss that results from stapes
fixation and progressive sensorineural deafness [10]. The human
gene POU3F4 is located in the X chromosome (Xql3-q22) being
one of the most frequent causes of X-linked deafness. In rats, the
Pou3f4 gene is expressed during embryonic development in the
brain, the neural tube, and the otic capsule at E15.5 and E17.5
days [11]. In mice, mutations of the homologous gene cause
similar defects as in humans. Loss of the tissues derived from the
otic mesenchyme was reported, as well as a shortening of the
cochlea suggesting that Pou3f4 might be required for epithelial-
mesenchymal interactions taking place during development
[12,13]. In humans, in addition to mutations in the coding region,
a hotspot 920 Kb 59 upstream of the POU3F4 gene was identified
where several microdeletions also caused DFN3 phenotype,
suggesting that regulatory regions were present in that region
[10,14–16]. Recently, using comparative genomics and transgenic
assays in different model systems, a POU3F4 enhancer within a
HCNR (HCNR 81728) was described to induce reporter
expression in the otic mesenchyme. This enhancer lay within the
smallest microdeletions shown to cause DFN3 [17,18]. However,
since not all microdeletions affect this enhancer [16,19], it was
hypothesized that other enhancers might be present in the hotspot
region. Reported in Naranjo et al. (2010) [18], we have identified
two additional enhancers at HCNR located within the 1 Mb 59
upstream of the Xenopus coding region, at position 970 Kb (HCNR
81675) and 170 Kb (HCNR 82478) of the pou3f4 coding unit that
present otic vesicle enhancer activity in a zebrafish transgenesis
assay. Here, we have analyzed the spatio-temporal activity of these
enhancers, as well as the signaling pathways that initiate their
activity. We found that the HCNRs display distinct temporal
patterns of activation and; while HCNR 81675 is regulated by the
retinoic acid (RA) signaling, the HCNR 82478 is regulated by the
Fgf pathway and the HCNR 81728 enhancer is under the control
of Hh. Finally we present direct evidence that the distal enhancer
is bound in vivo by Sox2 and Pax2 transcription factors. Altogether,
these data suggest that the regulatory apparatus of the pou3f4 is
multiple, complex and integrate distinct developmental inputs.
Materials and Methods
Ethics Statement
Zebrafish transgenic fishes have been maintained at the PRBB
Animal Facility. Our Animal Facility in accordance with national
and European regulations is registered as animal research center
with the number B9900073. Veterinary welfare supervision and
daily water check-ups are conducted (dissolved oxygen, conduc-
tivity, pH, ammonia, nitrites, nitrates, alkalinity and hardness -Kh
and Gh-, among other parameters) to ensure the animals good
health status. Temperature, humidity, light intensity and noise
control in the room are strictly monitorized to guarantee animal
welfare. Zebrafish embryos have been sacrificed after being
anesthetized with 0.016% tricaine when necessary. The experi-
mental zebrafish procedures have been performed following the
protocols (CEEA-PRBB ref JMC-07-1001-CPC and MM-08-
1108BAE) approved by the Ethical Committee for Animal
Research (CEEA) from Barcelona Biomedical Research Park
(PRBB) according to the European Union regulations.
Generation of transgenic zebrafish lines
pou3f4 HCNR 81675 and HCNR 82478 GFP zebrafish lines were
obtained as described in [18]. Briefly, both HCNRs were selected
based on high sequence conservation with human genome by
using VISTA browser (http://pipeline.lbl.gov/cgi-bin/gateway2).
Subsequently genome fragments were amplified by PCR from
Xenopus tropicalis, cloned into the PCR8/GW/TOPO vector and
stable zebrafish lines generated by the Tol2 transgenesis system.
Transgenic GFP detection
pou3f4 HCNR 81675 and HCNR 82478 GFP embryos were
staged according to morphology and somite pair number. For life
GFP imaging, tricaine-anesthesized embryos were mounted in
slides with glycerol and images were taken under the microscope.
Whole-mount in-situ hybridization
Whole-mount in-situ hybridization (WISH) was performed
according to standard protocols [20]. Briefly, dechorionated
zebrafish embryos were fixed in 4% paraformaldehyde overnight
at 4uC and dehydrated in methanol series, rehydrated again and
treated with 10 mg/ml proteinase K (Sigma) for 10 minutes.
Digoxigenin-labelled probes were hybridized overnight at 58uC,
detected using sheep anti-digoxigenin-AP antibody at 1:2000
dilution (Roche) and developed with NBT/BCIP (Roche).
Embryos were either used for imaging or embedded in tissue-tek
OCT (Sakura) for sectioning in a Leica CM1510-1 cryostat at
12 mm.
Inhibitor treatment assay
HCNR 81675 and HCNR 82478 GFP transgenic embryos
were chorion punctured and incubated with different pharmaco-
logical inhibitors in system water, from 5.5, 7.5 or 9.5 hours post-
fertilization (hpf) stage until 18–20 hpf or 36–40 hpf respectively.
The battery of inhibitors included: 30 and 50 mM SU5402
(Calbiochem) to inhibit Fgf signaling, 100 mM DAPT (Calbio-
chem) to inhibit Notch signaling, 20 mM DEAB (Sigma) to block
RA synthesis, 30 mM Dorsomorphin (Biomol) to inhibit Bmp
signaling and 45 mM cyclopamine A (CyA) to inhibit Hh signaling.
DMSO diluted at 1/200 in system water or EtOH 95% was used
as the carrier control treatment.
Immunostaining
For immunostaining after WISH, pou3f4 HCNR 81675
developed embryos were frozen in tissue-tek OCT and sectioned
(12 mm). Slides were fixed in 220uC methanol for 10 minutes and
blocked-permeabilized in 10% fetal bovine serum (FBS), 3%
bovine seric albumin (BSA) (Sigma) in 0.1% PBT (0.1% tween-20)
for 90 minutes at room temperature. Slides were stained with
rabbit anti-GFP (Takara) at 1:400 overnight at 4uC and donkey
anti-rabbit Alexa 488 (Molecular Probes) at 1:400 for 90 minutes
at room temperature, both in 0.1% PBT, 10% FBS, 3% BSA.
Sections were mounted in mowiol for imaging. For double
immunostaining, transgenic GFP was able to be detected after all
the processing, thus pou3f4 HCNR 81675 embryos were sectioned,
blocked-permeabilized and stained with mouse anti acetylated-
tubulin (Sigma T6793) or rabbit anti-Pax2 (Zymed laboratories
ref.71-6000) at 1:400 overnight at 4uC and goat anti-mouse Alexa
546 or goat anti-rabbit Alexa 594 (Molecular Probes) at 1:400 for
90 minutes at room temperature. Nuclei were stained with 496-
diamidino-2-phenylindole (DAPI, Molecular Probes) for 5 minutes
and mounted in mowiol.
FMH 4-64FX staining
Alive 3 day-old pou3f4 HCNR 81675 embryos were injected
into the otic vesicle with a micromanipulator with the FMH 4-
64FX reagent (Invitrogen) at 1:5 dilution in water, and then left in
system water for 15 minutes, fixed in 4% paraformaldehyde
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(Sigma) and frozen in tissue-tek OCT (Sakura) for sectioning and
imaging.
Transcription factor binding site (TFBs) prediction and
site-directed mutagenesis
In order to predict conserved TFB sites in the pou3f4 HCNR
81675 sequence, human and Xenopus sequences were analysed in
rVISTA 2.0 (http://rvista.dcode.org/) that predicts evolutionarily
conserved transcription factor binding sites. Moreover, the
sequence of Xenopus was also analysed by Transfac 7.0 in the
Gene Regulation portal (http://www.gene-regulation.com/index.
html). Pax2 and Sox2 binding sites found in the pou3f4 HCNR
81675 were subjected to site-directed mutagenesis. Based on the
Transfac motif and literature research, we mutated the core
nucleotides of the Pax2 and Sox2 binding sites by designing
primers that contained the Pax2 binding core GTGAATAG
mutated into TCAAACAT or the Sox2 binding core ACAAAA
mutated into GTGCTC. Mutant primers were used to introduce
these point mutations into the pCR8/GW/TOPO TAH - HCNR
81675 construct using the Quik ChangeH XL Site-Directed
Mutagenesis Kit (Stratagene). Transgenic zebrafish containing
either Pax2 or Sox2 mutant binding sites as well as the double
mutant for Pax2 and Sox2 motifs were generated using the ZED
vector and Tol2 transposon/transposase transgenesis method [21]
and F1 embryos were analyzed for the presence of inner ear GFP.
Chromatin ImmunoPrecipitation (ChIP) assay
Otic vesicle from stage 24 and stage 30 Xenopus embryos were
dissected and used for Chromatin immunoprecipitation assay. ChIP
analysis was performed with minor modifications as described
previously [22]. Chromatin was crosslinked with formaldehyde
(Merck), sheared into 200–500 base pairs fragments by sonication
with a Bioruptor Diagenode sonicator (medium speed, 8 minutes),
incubated overnight with rabbit anti-Pax2 (Zymed laboratories) and
rabbit anti-Sox2 (Abcam, Ab15830) antibodies and precipitated
with protein G/A-Sepharose (GE Healthcare). DNA-protein
complexes were decrosslinked and immunoprecipitated chromatin
was used for quantitative PCR performed using SYBR Green I
Master kit in a LightCycler480 system (Roche). PCR primers for the
Pax2 and Sox2 binding sites in the Xenopus pou3f4 HCNR 81675 were
designed (Sox2 forward TTCCAGTCTTTTCTTTTCCAAAGCT,
reverse TTTGCCTTTGGGCGTAATTT; Pax2 forward CAG-
CATCCATTTAATTCATCAAACA, reverse TGAAGTTTCT-
CTCTTCTGCAACTCTT), whereas primers for a CNR in the
Xenopus haemoglobin-2 locus with no predicted Pax2 and Sox2 binding
sites according to rVISTA and Transfac databases were used as
negative control (Xenopus scaffold_357:988236-988368; forward
TCTGCTCTCTTGTAGCTGCTGTCT; reverse ACTTGTCC-
CAGGCAGCTTGT).
Image acquisition
Pictures were acquired in a Leica DRM microscope using a
Leica DFC300 FX camera and the Leica IM50 software. Adobe
Photoshop CS2 software was used for photograph editing.
Results
pou3f4 inner ear enhancers activate gene expression at
different developmental stages
We have recently used comparative genomics and transgenic
assays in Xenopus and zebrafish to identify several highly
conserved non-coding regions (HCNR) in the 1 Mb 59 upstream
region of the pou3f4 transcription start site with enhancer activity
in the developing inner ear [18]. Here we use the same
nomenclature used in our previous work report. Thus, each
enhancer is named by their position in the human chromosome
X (hg18 version) in kilobases. HCNR 81675, 81728 and 82478
are located, respectively, at 970, 922 and 70 Kb apart from the
pou3f4 transcriptional start site (Figure 1A). We first determined
the onset of expression of each enhancer in stable zebrafish
transgenic lines harboring GFP under the control of each of these
cis-regulatory regions. In this and in our previous work [18], we
observed that GFP driven by the enhancer at HCNR 81728
became clearly visible at 72 hpf (data not shown). Since we are
particularly interested in early patterning events during inner ear
development, we have concentrated in the other two enhancers,
HCNR 81675 and HCNR 82478, which activate transcription
much earlier. To that end, embryos were assayed for GFP
expression every hour from 10.5 hours post-fertilization (hpf) to
18.5 hpf, and then again at 24 hpf and 36 hpf. Expression in the
inner ear was first detected in HCNR 81675 embryos of 13.5 hpf
(Figure 1B), whereas for HCNR 82478 otic GFP was not found
earlier than 18.5 hpf. Before initiating GFP expression in the
inner ear, the enhancer was active in the mesonephros at
17.5 hpf (Figure 1C). The HCNR 82478 also droved expression
in the midbrain-hindbrain boundary at 18.5 hpf and to the spinal
cord at 24 hpf (Figure 1C).
To check at which stage, both enhancers are functional at the
transcriptional level, whole-mount in situ hybridization (WISH)
to detect GFP mRNA was performed. WISH in the same stage
embryos revealed that, in both pou3f4 enhancers, GFP mRNA
transcription starts two hours before the GFP protein is
detectable, at 11.5 hpf and 16.5 hpf respectively (Figure 1D
and E). Thus, at the mRNA and at the protein level these results
indicate that both enhancers are functional and regulate reporter
gene expression to the otic vesicle (among other tissues in the case
of HCNR 82478) but they activate the expression at different
developmental stages.
Early activated pou3f4 enhancers promote expression in
inner ear sensory patches
Since both pou3f4 early expressed enhancers activate reporter
GFP expression at different developmental stages in zebrafish, we
next assayed whether the spatial pattern of expression in the inner
ear also presented particularities. From 13 hpf to 24 hpf, GFP
driven by HCNR 81675 is observed in almost the entire otic
placode (see Figure 1B). However, at 24 hpf a lateral view of the
otic vesicle revealed that higher expression is concentrated
ventrally, in a broad domain that includes the areas of anterior
and posterior otolith deposition (Figure 2A, otoliths indicated with
a star). Otoliths appear at 24 hpf and are particles of gelatinous
matrix and calcium carbonate that are deposited over the hair-
cells of the maculae, helping to the sense of gravity and linear
acceleration. On the other hand, expression promoted by HCNR
82478 at 24 hpf is already restricted to the sensory domain, as
judged by the correspondence with anterior and posterior otolith
(Figure 2D). When embryos reach the 3-day old stage, GFP
expressions driven by both pou3f4 HCNRs become restricted to
the two sensory maculae and the three sensory cristae associated to
the semicircular canals (Figure 2C and F).
Sensory patches are formed by hair-cells and supporting cells.
Thus, to determine whether GFP is restricted to any lineage of
the otic sensory patches or by contrast expressed in both cell
types, we performed staining either with an antibody against
Pax2 protein or with FM 4-64FX compound. In 3-day embryos,
the Pax2 protein is found only in hair-cells nuclei. On the other
hand, the FM 4-64FX compound stains hair-cell cytoplasm by
Novel Pou3f4 Enhancers: Expression and Regulation
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entering through ion channels of the stereocilia. Interestingly, in
the case of HCNR 81675 enhancer, GFP staining was observed
in supporting cells but excluded from hair-cells labelled with Pax2
or FM 4-64FX compound (shown in red in Figure 2G and I,
white arrows). However, in the case of HCNR 82478, GFP
staining was observed both in hair-cells and supporting cells
(Figure 2H and J; white arrows). GFP was also found in the otic
ganglion in HCNR 82478 (but not for HCNR 81675) transgenic
fishes as shown by cells co-immunostained with anti-GFP and
anti-Islet1 in neuroblasts anterior to the otic vesicle (Figure 2K
and L).
Distinct pou3f4 inner ear enhancers are under the control
of different signaling pathways
Next we decided to address which signaling pathway/s might
control the activation of the different pou3f4 enhancers in vivo.
Transgenic embryos for the HCNR 81675 enhancer were treated
from different temporal points with a battery of pharmacological
inhibitors of distinct signaling pathways. When embryos were
treated with inhibitors of the Fgf (SU5402), the RA (DEAB) and
Bmp (Dorsomorphin) pathways, smaller otic vesicles were
observed since all three pathways play essential roles in otic
placode formation [23–28]. In contrast, Notch (DAPT) and Hh
Figure 1. Temporal expression pattern of GFP driven by pou3f4 HCNR 81675 and HCRN 82478 enhancers. (A) Schematic representation
of the POU3F4 locus in the human chromosome X (hg18 alignment) showing the position of the different inner ear enhancers relative to the POU3F4
coding sequence. (B–C) Onset of GFP protein expression in HCNR 81675 (B) and HCNR 82478 (C) transgenic embryos. Expression in the otic territory
occurs at 13.5 hpf in HCNR 81675 and at 18.5 hpf in HCNR 82478 zebrafish embryos (white arrows), GFP in mesonephros and midbrain-hindbrain
boundary (red arrows) is also detected in HCNR 82478 embryos. (D–E) Dorsal views of HCNR 81675 (D) and HCNR 82478 (E) transgenic embryos
assayed by in-situ hybridization for GFP mRNA expression. In both cases GFP mRNA was detected in the otic field 2 hours before GFP protein was
found (B–C). Orientation of the embryos is anterior (left) to posterior (right).
doi:10.1371/journal.pone.0015907.g001
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(CyA) pathways inhibition did not have a major effect on the size
of the otic vesicle. Interestingly, the expression of GFP driven by
HCNR 81675 enhancer was only lost when RA signaling was
abrogated at 5.5 hpf (Figure 3A–G and 3O) but not at later stages
such as 7.5 hpf or 9.5 hpf (Figure S1), indicating that the HCNR
requires an early RA signal to be induced. Note that at these
stages, Fgf was inhibited at a low concentration of SU5402, since
at a concentration of 50 mM otic vesicle formation is severely
compromised due to the requirement of Fgf in otic induction [26–
29]. In situ hybridization for Fgf, Notch, RA, Bmp and Hedgehog
target genes such as pea3, neuroD, krox20, msx1 and ptc1 was done in
inhibitor-treated embryos to confirm that each signaling pathway
was abrogated at our working concentrations (Figure S2).
A similar experimental procedure was performed for the
HCNR 82478 enhancer. We treated the transgenic embryos with
the same battery of signaling pathway inhibitors from 5.5 hpf,
7.5 hpf (Figure S3) and 9.5 hpf stage to up to 36–40 hpf
(Figure 3H–N and 3P). In this case, embryos were incubated
until later stages when strong GFP signal in the otic vesicle is
detected. Interestingly, RA signaling blockade did not suppress the
activity of HCNR 82478 enhancer but instead GFP expression
was lost after Fgf signaling inhibition at all stages tested. These
data indicate that both enhancers are regulated independently and
are active under the influence of distinct developmental pathways.
In mice, Pou3f4 works in a cooperative manner with Tbx1
transcription factor to control cochlear growth [30] and
mesenchymal expression of Tbx1 has been shown to be under
the control of Shh [31]. Thus, we decided to test whether the
HCNR 81728 enhancer was also under the control of this pathway
in zebrafish transgenic lines. Note that in zebrafish, GFP
expression is mainly detected in the otic vesicle, with some
expression also at the mesenchyme (Figure 4A and [18]). We
found that, in contrast to the other enhancers, the HCNR 81728
enhancer displayed a strong reduction of the area of GFP
expression (expressed as % of GFP domain) after blockade of Hh
pathway by CyA (Figure 4A–C) suggesting that probably tbx1 and
pou3f4 share the same regulatory mechanisms.
GFP driven by the pou3f4 HCNR 81675 enhancer co-
localizes with pax2a and sox2 mRNA
To get more insight about the early events during inner ear
development, we then analysed in more detail how the earliest
Figure 2. Spatial-temporal expression pattern of pou3f4 enhancers in the inner ear. (A–F) Lateral views of inner ears from zebrafish
transgenic embryos for HCNR 81675 (A–C) and HCNR 82478 (D–F) enhancers analysed from 24 hpf to 72 hpf. In HCNR 81675 embryos at 24 hpf, GFP
is observed in two broad domains comprising the sensory territories as observed by the otolith deposition (stars) (B). In HCNR 82478, GFP is already
restricted to the anterior and posterior sensory macula from its onset as observed by GFP fluorescence relative to the otolith position (star). (C and F)
GFP is found in the three sensory crista in 3-day old embryos in both transgenic zebrafish lines. Orientation is anterior (left) and dorsal (up). (G and H)
Confocal transverse images of inner ear sensory patches immunostained with the anti-Pax2 antibody in 72 hpf embryos. In HCNR 81675 embryos,
GFP is found in supporting cells but absent in hair-cells (Pax2 positive cells; pointed by a white arrow) (G). In contrast, HCNR 82478 embryos displayed
GFP in supporting cells but also in hair-cells at lower levels (white arrow) whereas other hair-cells where completely devoid of GFP expression (red
arrow). (I and J) Transverse confocal images of sensory patches of both enhancer embryos immunostained for GFP after the injection of the hair cell
specific labelling marker FM 4-64FX. The same result was obtained in this experiment. (I) GFP is devoid in FM 4-64FX stained hair-cells in HCNR 81675
embryos (white arrow), whereas some hair-cells displayed GFP in HCNR 82478 embryos (J; white arrow). (K and L) Confocal images taken from the
transverse section anterior to the first section from the otic vesicle. Co-immunostaining for anti-GFP and anti-islet1 protein reveals that only in HCNR
82478 transgenic embryos GFP is activated in the otic ganglion (L). (G–L) Lateral (left) and dorsal (up).
doi:10.1371/journal.pone.0015907.g002
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inner ear enhancer we have described, that located at HCNR
81675, is controlled. First, we compared the expression pattern
promoted by this enhancer with that of several genes regionally
expressed in the otic vesicle. We performed in situ hybridization of
embryos of 13, 15 and 18 hpf for pax2a, sox2, sox10 and tbx1 and
compared the patterns with GFP protein staining in HCNR 81675
Figure 3. Distinct signaling pathways regulate activation of pou3f4 HCNR 81675 and HCNR 82478 enhancers. (A–N) Transgenic
embryos for both enhancers were treated with different pharmacological inhibitors from 5.5 hpf stage to 18–20 hpf and 7.5 hpf to 36–40 hpf
respectively. Lateral view of HCNR 81675 (A–G) 18–20 hpf staged otic vesicles and HCNR 82478 (F–N) otic vesicles of 36–40 hpf embryos. HCNR 81675
activity was abrogated in the presence of RA signaling inhibitor DEAB (compare D to the control treatment with DMSO in A), whereas Fgf signaling
inhibition by SU5402 completely disrupted pou3f4 HCNR 82478 activity (compare I to control treatment in H). Orientation is anterior (left) to posterior
(right). (O, P) Graphs representing the percentage of embryos displaying complete inhibition of GFP expression in pou3f4 HCNR 81675 (O) and HCNR
82478 (P) transgenic embryos after specific signaling pathway blockade. The total number of embryos counted in three independent experiments is
represented.
doi:10.1371/journal.pone.0015907.g003
Figure 4. The POU3F4 HCNR 81728 enhancer is regulated by Hedgehog signaling. (A and B) Lateral view of GFP otic expression in 96 hpf
embryos transgenic for the HCNR 81728 enhancer in control (A) and Cyclopamine A treated embryos (B). (C) Percentage of GFP expressing area in
otic vesicles from 95% EtOH and Cyclopamine A treated embryos.
doi:10.1371/journal.pone.0015907.g004
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transgenic animals. GFP was found in the medial otic domain also
stained for pax2a (Figure 5A and D). Sox2, although more restricted
to an anterior and a posterior medial region, was also found in the
same medial domain as GFP (Figure 5B and D). However, there
was no correlation with the other tested genes, since sox10 was
expressed all over the otic vesicle (Figure 5C) and tbx1 was
expressed in a lateral domain (data not shown). These results were
further confirmed by double labelling experiments. Double
immunostaining with anti-GFP antibody and anti-Pax2a showed
co-localization of both proteins in the same domain (Figure 5E–
E0), while anti-GFP immunostaining after in situ hybridization for
sox2, sox10 and tbx1 transcripts in 15 hpf embryos revealed only
co-expression of GFP and sox2 transcripts (Figure 5F–F0). No exact
correspondence with sox10 (Figure 5G–G0) and tbx1 domains of
expression was found. Indeed, tbx1 and GFP expression domains
were mutually exclusive (Figure 5H–H0).
As aforementioned, we found that the HCNR 81675
enhancer activity is regulated by retinoic acid. Thus, to
determine whether the GFP inhibition by DEAB (retinoic acid
inhibitor) observed in embryos transgenic for the HCNR 81675
enhancer, correlated with abrogation of pax2a and/or sox2 gene
expression, in situ hybridization for these two genes as well as
for sox10 and neuroD was performed after DEAB treatment.
Indeed, RA inhibition by DEAB leaded to a complete loss of
pax2a and sox2 expression in the otic vesicle, whereas sox10 and
neuroD expression was similar to the DMSO-treated control
embryos (Figure 5I–P). All together, these results suggest that
pax2a and sox2 expression regulated by RA signaling would be
required for the proper cis-activation of the HCNR 81675
enhancer in the otic vesicle.
Pax2 and Sox2 are directly recruited to the pou3f4 HCNR
81675 DNA and are required for its function
Since pax2a and sox2 are co-expressed in a similar domain than
that promoted by the HCNR 81675 enhancer and retinoic acid
inhibition results in loss of both, GFP and pax2a and sox2
expression, we then checked for Pax2 and Sox2 binding sites in the
HCNR 81675 genomic sequence. TRANSFAC analysis of human
and Xenopus HCNR 81675 sequences revealed a high number of
Figure 5. Co-localization of Pax2 and Sox2 with GFP driven by the HCNR 81675 enhancer. (A–D) Dorsal view of transgenic embryos
assayed by ISH for the expression of pax2a (A), sox2 (B), sox10 (C) at 13, 15 and 18 hpf. GFP (D) displays a similar pattern than sox2 and pax2a at 15 hpf
(compare A and B with D). Orientation is anterior to the left. (E–E0) Double immunostaining with anti-Pax2 (E) and anti-GFP antibody (E9) in transverse
sections of 15 hpf otic vesicles revealed co-localization of both proteins (E0). (F–F0) GFP protein (F9) also co-localizes with sox2 mRNA (F0) but not
sox10 or tbx1 mRNA (G0 and H0). (I–P) pax2a and sox2 expression is abolished in retinoic acid treated HCNR 81675 embryos (compare J and L to I and
K, respectively) but not other genes such as sox10 or neuroD (compare N and P to M and O, respectively). Dorsal view, orientation is anterior to the
left.
doi:10.1371/journal.pone.0015907.g005
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conserved putative Transcription Factor Binding Sites (TFBS).
Interestingly for the work presented here, a putative Sox motif and
two Pax2/5/8 motifs where found in the sequence (Figure 6A). To
check whether Pax2 and Sox2 proteins are directly bound to this
HCNR 81675 in vivo, we performed chromatin immunoprecipi-
tation assay (ChIP). PCR primers were designed to include the
region of Pax2 and Sox2 binding sites. Otic vesicles from stage 30
to 34 Xenopus embryos were dissected and the chromatin was
immunoprecipitated with either rabbit anti-Pax2 and rabbit anti-
Sox2 antibodies or rabbit IgG as control. Figure 6B shows that the
pou3f4 HCNR 81675 DNA was precipitated by the anti-Pax2 and
anti-Sox2 antibodies but not by the isotopic antibody. Moreover,
no binding of these two proteins in the Xenopus haemoglobin
promoter which lacks Pax2 and Sox2 binding sites was detected,
confirming the specificity of Pax2 and Sox2 binding to the
endogenous Xenopus HCNR 81675 (Figure 6B and quantitative
PCR results shown in Figure 6C).
Finally, to further confirm that Pax2 and Sox2 proteins are
required for the in vivo functionality of the HCNR 81675
enhancer, we designed primers containing mutations in the core
nucleotides of the Sox2 and Pax2 binding sites (Figure 7A) and
we performed site-directed mutagenesis of these sites in the
HCNR 81675 sequence. Stable zebrafish transgenic lines were
generated with a construct containing the GFP gene under the
control of the pou3f4 HCNR 81675 enhancer harbouring either
the mutation for the Pax2 or Sox2 binding sites as well as double
mutants. As shown in Figure 7B and 7C, GFP was dramatically
reduced when both the Pax2 and Sox2 binding sites are
mutated, but not in the Pax2 or Sox2 single mutants (data not
shown), indicating that both proteins are directly bound to the
pou3f4 HCNR 81675 DNA region and required for its enhancer
activity.
Discussion
Hearing impairment is one of the most prevalent sensorineu-
ral defects in humans and in the last years many human ear
disorders have been linked to mutations in over a hundred
different genes [32,33]. One of the most frequent causes of X-
linked hereditary deafness is caused by mutations in the
POU3F4 locus. It has been described that mutations leading to
X-linked deafness type 3 (DFN3) syndrome not only affect the
POU3F4 coding sequence [16] but also upstream non-coding
regions, since many human patients displaying sensorineural
hearing loss contain microdeletions in a region 1 Mb 59
upstream of the POU3F4 gene. Accordingly, we and others
have recently identified several pou3f4 inner ear enhancers
within this genomic region [17,20]. In this work, we show that
Figure 6. Pax2 and Sox2 are directly recruited to the HCNR 81675 DNA. (A) rVista 2.0 alignment of HCNR 81675 human and Xenopus
genomic sequence. Conserved binding sites for Sox and Pax2/5/8 proteins found by TRANSFAC are represented. Primer location enclosing the
genomic region of Sox and Pax2/5/8 binding sites designed for chromatin immunoprecipitation are marked with red and violet arrows respectively.
(B) ChIP with anti-Pax2 and anti-Sox2 antibodies from stage 30–34 Xenopus otic vesicles was performed and the PCR amplification of the DNA
fragments pulled down by Pax2 and Sox2 chromatin immunoprecipitation is shown. A region of the haemoglobin locus with no Pax2 and Sox2
binding sites shows no immunoprecipitation with these antibodies. (C) Graphs representing the relative fold enrichment of Sox2 and Pax2 binding to
the HCNR 81675 but not to the haemoglobin region detected by quantitative PCR.
doi:10.1371/journal.pone.0015907.g006
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these enhancers have distinct spatio-temporal activities and are
activated by different signaling pathways.
Several pou3f4 enhancers drive otic vesicle expression
Previous work published by Ahn and colleagues described a
human HCNR that specifically directs POU3F4 expression mainly
to the periotic mesenchyme in transgenic lacZ mouse embryos
[17]. By screening for HCNR over a region of 1 Mb 59 upstream
of the POU3F4 coding unit several other evolutionary conserved
sequences (from human to Xenopus) were identified [20]. In
transgenic zebrafish, Xenopus HCNR 81675 and HCNR 82478
specifically drive reporter GFP expression to the otic epithelium
and at later stages to the inner ear sensory patches. HCNR 81675
directs reporter gene expression only to the otic vesicle, while
HCNR 82478 acts as a general enhancer driving pou3f4 expression
to all the tissues where it is expressed such as the otic vesicle,
midbrain-hindbrain boundary, mesonephros and spinal cord.
Both new otic enhancers are at each side of the previously
identified POU3F4 enhancer [17]. Thus, three different enhancers
drive pou3f4 expression to the otic territory indicating that Pou3f4
is a crucial transcription factor for inner ear development and that
its expression needs very fine-tuned regulation. This is further
exemplified by its distinct temporal activity. In stable transgenic
fishes, GFP in the otic vesicle is switched on at different
developmental stages, being the enhancer at HCNR 81675 active
before the one at HCNR 82478, and this one before the regulatory
element located in HCNR 81728. Moreover, transcriptional
activation directed by the HCNR 82478 enhancer starts in the
mesonephros, followed by activity in the midbrain-hindbrain
boundary and finally to the otic vesicle. Later on, at 24–32 hpf
GFP is no longer detected in the mesonephros and in contrast it is
activated in the spinal cord.
It has been well reported that developmental genes are very
tightly regulated and thus in their loci several scattered enhancers
are contained around or in the gene that regulate. Examples are
found in the locus of the Hox and Irx gene clusters or the Sox2 gene
[34,35]. In the case of Sox2, Kondoh and colleagues have nicely
dissected out the genomic regulatory apparatus of the chicken Sox2
locus. Eleven enhancers were identified and from those, three and
two enhancers control the expression of Sox2 in the spinal cord and
otic placode, respectively.
Different regulation and temporal activation of both otic
epithelium enhancers
Inner ear development is highly complex and many distinct
signaling pathways regulate it. Fgf signaling for example is used
throughout ear development to control distinct processes, initially
is essential for the induction of the otic primordium from the
ectoderm. In zebrafish embryos, loss of fgf3 and fgf8 results in
complete ablation of the otic placode, while in chick and mice Fgfs
from the mesoendoderm primarily control the process [26–29,36–
38]. Later on, different Fgfs participate in inner ear neurogenesis,
growth and morphogenesis [39–43]. Blockade of Fgf signaling by
SU5402 did affect the size of the otic vesicles of both enhancer
transgenic fish due to its role in otic growth and placode
formation. GFP expression driven by HCNR 82478 but not by
HCNR 81675 was suppressed by the pharmacological inhibition
of the Fgf pathway at late gastrula stages. The activation of HCNR
82478 by Fgf signaling probably reflects a late role of Fgf in
sensory development as several Fgfs are expressed in sensory
patches in higher vertebrates [39,43]. In contrast, the activity
HCNR 81675 required the integrity of RA pathway at early
gastrula stages but not at later stages. RA is synthesized in the
paraxial mesoderm and influences hindbrain and ear development
[44–46]. In zebrafish, treatment of embryos with low levels of RA
causes expansion of the otic field, suggesting that RA has a role in
limiting the field to respond to otic inducing signals [23].
Moreover, RA has also a positive action in the regeneration and
generation of hair-cells [47,48]. RA in addition to regulate otic
development directly, at early gastrula stages is necessary for
proper hindbrain patterning and establishment of hindbrain fgf
expression [23,26]. Thus, the role of RA on the activity over the
HCNR 81675 might be indirect through the disruption of
hindbrain signals and the synergistic effect of inhibiting RA and
Fgf pathway at 5.5 hpf. At 9.5 hpf, both pathways are indepen-
dent, in agreement with a independent regulation of the HCNR
82478 enhancer by Fgf but not RA pathway. Notch pathway has a
crucial role in the specification of the sensory domains in several
vertebrate species [49,50], while BMP4 regulates the generation of
the hair-cells in the sensory patches [51,52]. For this reason, was
surprising that none of the enhancers was affected by Notch or
BMP inhibition. Interestingly, the late enhancer at HCNR 81728
is regulated by Hh. This would be in agreement with previous
findings in which was shown that Shh signaling secreted by the
notochord and/or floor plate is required for the specification of the
cochlea [53]. Several data suggest that the newly found regulation
of Hh over the HCNR 81728 enhancer might be mediated by
Tbx1 transcription factor: first, we show a regulation of Hh over
the human POU3F4 mesenchymal enhancer; second, previous
reports in mice indicated that Pou3f4 cooperates with Tbx1 during
cochlear development [30]; third, Pou3f4 expression is reduced in
Figure 7. Pax2 and Sox2 proteins are required for HCNR 81675
enhancer activation. (A) Scheme showing wild-type Sox and Pax2/5/
8 consensus in the pou3f4 HCNR 81675 sequence and above each one,
the mutation in the primers designed for site-directed mutagenesis of
the Sox and Pax2/5/8 binding sites. (B–C) Transgenic embryos carrying
GFP under the control of the HCNR 81675 enhancer. (B) GFP expression
promoted by the wild type HCNR 81675 sequence. (C) GFP expression
promoted by the HCNR 81675 enhancer harbouring the double
mutation for Pax2/5/8 and Sox binding sites.
doi:10.1371/journal.pone.0015907.g007
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conditional Tbx1 mutants [54] and, finally Tbx1 mesenchymal
expression is regulated by Shh [31]. Thus, here we provide for the
first time an overall analysis of the signaling pathways that impact
on pou3f4 expression, acting separately over distinct enhancers
located at different HCNRs.
HCNR 81675 enhancer activity requires Pax2 and Sox2
GFP driven by pou3f4 HCNR 81675 co-localized with the pax2a
and sox2 expression domains in the otic vesicle. Since Sox and Pax
but not Tbx binding sites were found in the HCNR 81675
sequence, we hypothesized that both Pax2 and Sox2 might be
activating the enhancer in the zebrafish transgenic line. This was
confirmed by chromatin IP and site-directed mutagenesis of the
Pax2 and Sox2 binding sites that showed that Pax2 and Sox2 TF
are bound directly to the enhancer and regulate GFP expression in
vivo. Altogether, our results suggest that early pou3f4 expression
directed by the HCNR 81675 enhancer may be regulated by
retinoic acid and Sox2 and Pax2 transcription factors. Our
mutagenesis analysis of the HCNR 81675 enhancer plus the fact
that GFP is only found in domains of pax2a and sox2 co-
expression, indicate that Pax2 and Sox2 transcription factors alone
are not sufficient to activate this enhancer and act in a cooperative
manner over the genomic locus. This would be similar to what has
been reported by the cooperative interaction of Pax6 and Sox2 in
the d-crystallin and N3 Sox2 enhancers [55].
Endogenous pou3f4/Pou3f4 gene is expressed in the midbrain-
hindbrain boundary, mesonephros and spinal cord, as well as the
periotic mesenchyme in Xenopus and mouse embryos [13] (Figure
S4). Several possibilities might explain the difference between the
endogenous pou3f4 expression in the periotic mesenchyme and
the activation of the pou3f4 enhancers in the otic epithelium in
zebrafish. First, endogenous pou3f4 transcripts might be present in
the otic epithelium at lower and undetectable levels by in situ
hybridization; secondly developmental differences of expression
might appear when enhancers are extracted from their genomic
context. The latter hypothesis of an improper regulation of
foreign enhancers is favoured by the fact the human enhancer
described by Ahn et al. 2009 when inserted in mice [17] drives
ectopic lacZ expression in the spiral ganglion in addition to the
mesenchymal expression and in zebrafish (our manuscript and
[20]) expression is mainly found in the otic vesicle. Moreover, it
has been recently hypothesized that fine-tune gene expression
required during embryogenesis would be the result of the
synergistically interaction of different enhancer elements in a
combinational manner [56]. Following this notion, large genomic
regions containing several regulatory elements have under-
representation of nucleosomes suggesting a higher-order genomic
structure [57,58].
In conclusion, the description of the spatiotemporal activity of
novel enhancers of POU3F4 gene and their regulation may
contribute to the further understanding of the function of
POU3F4 in inner ear and its implications in DNF3.
Supporting Information
Figure S1 HCNR 81675 activity is not dependent on RA,
Fgf, Notch, Bmp and Hh at 7.5 and 9.5 hpf. (A–N) GFP is
observed after treatment of HCRN 81675 transgenic embryos
with pharmacological inhibitors of signaling pathways at 7.5 hpf
(A–G) and 9.5 hpf (H–N). Orientation is anterior to the left and
dorsal up.
(TIF)
Figure S2 Abrogation of different signaling target genes
after treatment with specific signaling inhibitors. (A–J) In
situ hybridization for the Fgf, Notch, Retinoic Acid, BMP and
Sonic Hedgehog target genes pea3 (A–B), neuroD (C–D), krox20 (E–
F), msxC (G–H) and ptc1 (I–J) to confirm inhibitor activity at our
working concentrations. Dorsal view, orientation is anterior to the
left.
(TIF)
Figure S3 HCNR 82478 activity is dependent on Fgf
signaling when treated at 5.5 and 7.5 hpf. (A–N) GFP is
inhibited after treatment of HCRN 82478 transgenic embryos
with 30 mM SU5402 at 5.5 hpf (A–G) and 50 mM SU5402 at
7.5 hpf (H–N). Orientation is anterior to the left and dorsal up in
all images.
(TIF)
Figure S4 Endogenous expression pattern of pou3f4/
Pou3f4 in Xenopus and mouse. (A–B) In situ hybridization for
pou3f4 mRNA in Xenopus embryos of stage 35 (A) and stage 42 (B).
Note that the endogenous expression is detected at the periotic
mesenchyme at stage 42, whereas at stage 35 pou3f4 is still not
expressed. (C–D0) In situ hybridization for Pou3f4 mouse mRNA
in mice embryos of stage E8.5 (C) and E16.5 (D). In mice, also
Pou3f4 is expressed at the otic mesenchyme at later stages, shown
in insets (D9, D0). Transverse sections shown in all panels.
(TIF)
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